Van ECK Associates Corp Has $15.96 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Van ECK Associates Corp lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 67,818 shares of the biopharmaceutical company’s stock after buying an additional 10,419 shares during the quarter. Van ECK Associates Corp’s holdings in Alnylam Pharmaceuticals were worth $15,958,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Values First Advisors Inc. grew its holdings in Alnylam Pharmaceuticals by 2.3% during the 4th quarter. Values First Advisors Inc. now owns 8,992 shares of the biopharmaceutical company’s stock worth $2,116,000 after acquiring an additional 202 shares during the period. Summit Trail Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 13.3% during the 4th quarter. Summit Trail Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 151 shares in the last quarter. Savant Capital LLC grew its stake in Alnylam Pharmaceuticals by 57.6% during the fourth quarter. Savant Capital LLC now owns 11,738 shares of the biopharmaceutical company’s stock worth $2,762,000 after purchasing an additional 4,291 shares during the period. Empowered Funds LLC increased its holdings in Alnylam Pharmaceuticals by 8.0% in the fourth quarter. Empowered Funds LLC now owns 7,630 shares of the biopharmaceutical company’s stock worth $1,795,000 after purchasing an additional 566 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after purchasing an additional 8,462 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,964 shares of company stock worth $20,622,925 in the last quarter. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ALNY. Scotiabank reduced their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $299.43.

Alnylam Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ:ALNY opened at $256.45 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a market capitalization of $33.08 billion, a PE ratio of -97.88 and a beta of 0.35. The business has a fifty day moving average price of $254.03 and a two-hundred day moving average price of $263.35. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.